Receive our newsletter – data, insights and analysis delivered to you
  1. News
June 1, 2016

Myriad Genetics buys Sividon Diagnostics for €50m

US-based molecular diagnostics company Myriad Genetics has acquired breast cancer prognostic company, Sividon Diagnostics in a deal valued at €50m.

US-based molecular diagnostics company Myriad Genetics has acquired breast cancer prognostic company, Sividon Diagnostics in a deal valued at €50m.

The transaction was done for €35m with a potential additional investment of €15m conditioned on achieving performance-based milestones.

Myriad is planning to fund the transaction on an all-cash basis and expects that the transaction will cast no effect on the company’s revenue and earnings in fiscal year 2017.

"The EndoPredict test will be the foundational product of our newly initiated kit-based strategy and allow Myriad to leverage its global oncology distribution to bring this important test to patients worldwide."

The transaction has added to Myriad’s portfolio of oncological devices, such as Sividon’s EndoPredict test which is a kit-based RNA expression test measuring the gravity of breast cancer on a molecular level and assists the patients to decide whether to avoid chemotherapy.

Myriad is planning to integrate the product on their Thermo Fisher QuantStudio platform which is currently CE Marked on the Siemens Versant instrument.

Myriad Genetic Laboratories president and CEO Mark Capone said: "The EndoPredict test will be the foundational product of our newly initiated kit-based strategy and allow Myriad to leverage its global oncology distribution to bring this important test to patients worldwide."

Content from our partners
Precision wire: The future of bespoke medical treatment
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success
“This technique means everything to us”: How CGM devices empower users 

The company seeks to increase the market footprint of EndoPredict which they project is greater than $600m with its majority existing in European countries, Canada, and the US.

About 4,000 patients have been subjected to the EndoPredict test and used by more than 13,000 patients exhibiting the product’s ability to determine which patients are at low risk for distant metastases in both node negative and node positive patients.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. The top stories of the day delivered to you every weekday. A weekly roundup of the latest news and analysis, sent every Friday. The medical device industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU